You can also read the IBTA e-News June 2019 edition in full online here.
Some of the highlights from this month's round-up:
- The bipartisan US Senate Resolution 245 has designated 17 July as 'Glioblastoma Awareness Day'. This will help raise public awareness of glioblastoma and encourage support for research, treatment development, patients and their families.
- GBM AGILE (Adaptive Global Innovative Learning Environment) is an innovative trial design that evaluates several potential treatments for glioblastoma at the same time and compares them against a control group. Regorafenib will be the first drug to be tested in this way and the study will start enrolling patients shortly.
- The German Institute for Quality and Efficiency in Healthcare (IQWiG) has published its rapid report concluding that, based on a review of Novocure's EF-14 phase 3 pivotal trial, patients with newly diagnosed glioblastoma lived longer when treated with Optune in addition to standard chemotherapy without affecting their quality of life.
- Survivors of childhood brain tumours who received radiotherapy, and were very young at the time of diagnosis, may experience cognitive and socioeconomic burdens decades after treatment, according to a study published early online in CANCER.
- Patients with isocitrate dehydrogenase mutated anaplastic astrocytoma appear to benefit most from concurrent and adjuvant temozolomide, according to results from a second interim analysis of the CATNON trial which were presented at ASCO in Chicago earlier this month. Ongoing molecular analyses and further follow up will enable researchers to assess the effectiveness of this treatment in molecular subgroups.
- Patients with recurrent low-grade and anaplastic ependymomas of the brain and spinal cord may be eligible to enrol in a new phase 2 clinical trial at the National Institutes of Health Clinical Center in the US. The trial will investigate marizomib, a second generation, irreversible proteasome inhibitor that targets ependymomas which have a specific genetic signature.
- Results from a single-arm, phase 2 trial of SurVaxM in 63 patients with newly diagnosed glioblastoma, who underwent craniotomy with near-total resection demonstrated encouraging efficacy and immunogenicity.
Our monthly e-News highlights items of interest to our international brain tumour community and is emailed to nearly 6,000 recipients. It gives a round-up of the latest research and treatment developments, news about brain tumour patient organisations around the world, and key forthcoming neuro-oncology scientific and patient conferences. You can sign up to receive the e-News every month by registering here.
To see an archive of existing e-News issues, click here.